Baxter's most recent trend suggests a bullish bias. One trading opportunity on Baxter is a Bull Put Spread using a strike $69.50 short put and a strike $64.50 long put offers a potential 9.17% return on risk over the next 24 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $69.50 by expiration. The full premium credit of $0.42 would be kept by the premium seller. The risk of $4.58 would be incurred if the stock dropped below the $64.50 long put strike price.
The 5-day moving average is moving up which suggests that the short-term momentum for Baxter is bullish and the probability of a rise in share price is higher if the stock starts trending.
The 20-day moving average is moving up which suggests that the medium-term momentum for Baxter is bullish.
The RSI indicator is at 41.57 level which suggests that the stock is neither overbought nor oversold at this time.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Baxter
BAXTER INTERNATIONAL INC Files SEC form 10-Q, Quarterly Report
Wed, 29 Oct 2014 21:06:11 GMT
Baxter International Gets FDA Nod for Hemophilia A Drug
Mon, 27 Oct 2014 21:45:01 GMT
UPDATE 1-Baxter's blood disorder drug gets FDA approval (Oct 24)
Mon, 27 Oct 2014 15:29:35 GMT
Reuters – Eloctate is approved to treat congenital hemophilia A, not acquired hemophilia A) Oct 24 (Reuters) – Drugmaker Baxter International Inc said the U.S. Food and Drug Administration had approved its drug for treating bleeding episodes in adults with a rare bleeding disorder.
FDA Approves Baxter’s OBIZUR [Antihemophilic Factor (Recombinant), Porcine Sequence], for Acquired Hemophilia A
Fri, 24 Oct 2014 14:08:42 GMT
noodls – FDA Approves Baxter's OBIZUR [Antihemophilic Factor (Recombinant), Porcine Sequence], for Acquired Hemophilia A Approval Based on Data Showing 100% of 28 Patients Responded to Treatment within 24 Hours …
Baxter's blood disorder drug gets FDA approval
Fri, 24 Oct 2014 13:35:36 GMT
Reuters – Drugmaker Baxter International Inc said the U.S. Food and Drug Administration had approved its drug for treating bleeding episodes in adults with a rare bleeding disorder. The drug, Obizur, has been approved for use in patients with acquired hemophilia A, which usually affects older adults, Baxter said in a statement.
Also on Market Tamer…
Follow Us on Facebook